Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 Continues to be on track to initiate first-in-human clinical trials mid-2024 Cash balance of $39.6 million as at December 31, 2023 TORONTO / Mar 27, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a regenerative medicine company aimed at... Read More